Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Actinogen Medical ( (AU:ACW) ).
Actinogen Medical announced a live webinar to discuss recent progress and upcoming milestones, highlighting the development of their lead compound, Xanamem, for Alzheimer’s Disease and Depression. The company is conducting clinical trials in Australia and the US, with promising results from previous studies showing significant benefits in depression symptoms and cognitive function. The ongoing trials aim to further validate Xanamem’s efficacy and safety, potentially impacting the treatment landscape for these debilitating conditions.
More about Actinogen Medical
Actinogen Medical is an ASX-listed biotechnology company focused on developing novel therapies for neurological and neuropsychiatric diseases linked to dysregulated brain cortisol. Their primary product, Xanamem, is being developed as a treatment for Alzheimer’s Disease and Depression, with potential applications for Fragile X Syndrome and other conditions. The company aims to address the substantial unmet medical need for improved treatments in these areas.
YTD Price Performance: 44.00%
Average Trading Volume: 2,810,575
Technical Sentiment Signal: Buy
Current Market Cap: A$114.3M
Learn more about ACW stock on TipRanks’ Stock Analysis page.